MedTrace Logo

Penicillin to Prevent Early Rheumatic Heart Disease in School-Aged Children

NCT07798232 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 9622

Last updated 2026-09-03

No results posted yet for this study

Summary

This study will look at whether children ages 5-8 who take Penicillin V by mouth twice a day are less likely to develop rheumatic heart disease (RHD) over a 3-year period compared to children who do not take the medicine.

Conditions

  • Rheumatic Heart Disease in Children

Interventions

DRUG

Oral Penicillin V

Twice-daily oral Pen V 250 mg

Sponsors & Collaborators

  • The University of Western Australia

    collaborator OTHER

  • Uganda Heart Institute

    collaborator OTHER

  • Ochsner Health System

    collaborator OTHER

  • Murdoch Childrens Research Institute

    collaborator OTHER

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Joselyn Rwebembera · Uganda Heart Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
8 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2027-02-01
Primary Completion
2031-07-31
Completion
2032-03-01
FDA Drug
Yes

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07798232 on ClinicalTrials.gov